GlobalTech.City is founded in 2017 and is the global platform connecting AmsterdamTech.City and the other tech cities around the world. VISION & MISSION The vision of AmsterdamTech.City is to combine city events, tech topics, societal challenges, tech solutions, and speakers for the city, communities, and citizens of Amsterdam. The mission of AmsterdamTech.City is to facilitate the city, communities, and citizens in the engagement and transformation. COMMUNITY The target groups are public and private; governmental and non-governmental; educational institutions, teachers and students; corporates, scale ups and start ups; investors and programs, inventors and experts; visitors and citizens. The speakers are presenting challenges and solutions. They are government officials, civil servants, citizens, visitors, students, teachers, experts, inventors, investors, start ups, scale ups, corporates. TECHNOLOGY The latest technology trends are the topics of the events and solutions. In 2016 the tech trends were Internet of Things (IoT), Artificial Intelligence (AI), Blockchain, and Big Data. In 2017 more tech trends will follow. The events are called “Tech & The city” where tech is replaced by the tech topic. The challenges are city or civic problems and issues. Examples are Education, Health, Mobility / Transportation, Connectivity, Sustainability, and many more. The solutions are tech solutions for the city or civic problems and issues. The tech solutions are based on the latest tech trends.

1. Unlocking the value
of (bio)medical and
healthcare
innovations
Dr. Bert Vrijhoef | CIO
on behalf of the Panaxea Team
The Health Intelligence Company

2. (Bio)Medical and Healthcare Innovation:
a Changing Game

3. A Changing Game
Notwithstanding the increasing need for innovation in health
care:
• Having something new (combined with provider or patient
pull) is just not sufficient anymore
• Getting an innovation to the clinic is increasingly dependent
on:
– How the innovation holds up in the era of (comparative)
evidence-based medicine
– Setting and managing a sustainable target price, based on the
innovations’ added value
– Payers have become players

4. Payers have become players
It is not enough to know:
– That an innovation ought to work
– That it makes sense
– That we can do it, or that an expert vouches for it
– That it works in mice, rats or petri dishes
It is nice to know, but still not sufficient:
– That it lowers blood pressure, normalizes heart rhythms, ...
– That it has better imaging or diagnostic quality
Instead, they need to know:
– Does it actually extend lives and/or improve quality of life?
– What are the risks, potential harms?
– What are the net changes in total costs of care including upfront
and downstream cost impacts?

5. Payers have become players
Payers want to be convinced about “value
for money” before the innovation enters
next development stages or clinical practice
Do
not
adopt
Trade-
off
Trade-
off
Adopt
costs
effects
+
−
+
−

6. Payers and other players
▪ Different stakeholders experience different benefits and burdens
▪ Stakeholders have different decision drivers and evidence needs

7. Panaxea
Addresses questions regarding:
▪ Business development and strategy
▪ (Re-)design of new service, product, or pathway
▪ Implementation of new service, product, or pathway
▪ Added value of new services, products, or pathways
▪ Market access & reimbursement
▪ Implementation/ evaluation of new products/
interventions in care pathway
“Intuitively, my product means
enormous value to the patient. How
do I convey the added value
potential of my product the
stakeholders including investors,
payers, patients health care
providers?”
“Users are complaining about the high
cost of the product, but they do not
realize the cost savings down the care
pathway. How can I clarify this?”
“My product is not taken up
by healthcare providers.
How can I increase market
penetration?”
“What is the savings
potential of my product?”
“What is a an acceptable,
value-based price range for
my new product?”

8. Strategic Market Access
▪ Panaxea offers strategic advice in early
stage of a company’s product development
process to accelerate market access.
Unlocking the value of your
(bio)medical and healthcare
innovations
▪ Focuses on:
– Accelerating patient access to
(bio)medical innovations
– Building scientific evidence to inform
strategic development, pricing and
reimbursement decisions
– Evaluate and monitor health care
innovations or pathways
▪ With state-of-the-art academic
methodology/ tools Panaxea provides
excellence in services such as:
Health Economic Modeling
▪ Panaxea offers health economic expertise to
model clinical, economic and humanistic
impact, even at the earliest stages of
biomedical product development.
New Models of Care Delivery
▪ New care models incl. integration of social
and health care, pathways, bundled
payments;
▪ Substitution of care between health-care
professionals and organizations incl.
transitions of care and self-care;
▪ E-health: new business models,
implementation fidelity, cost-effectiveness.

9. Payback from research analysis;
Strategic business case;
Conceptualization of new models of
care delivery;
Multi-criteria decision analysis;
Health economic evaluations;
Health services and policy research;
Horizon scanning;
Clinical trial simulation;
Value of Information analysis;
Reimbursement strategy and
planning;
Value dossiers
D – Implementation and
monitoring of new models of care
delivery;
Health services and policy research
Panaxea along the Medtech Product Development Process
R&D
decision
Observed
need
Investment
decision
Market
decision
Concept
development
Product
development
Post market
development
A B DC
A – Market Analysis;
Priority setting
B – Headroom analysis
C – Product development support;
MTA or health economic model;

10. Projects
Selection of projects
Developing an innovative in-vitro diagnostic medical device for early diagnosis of Lyme
disease
Problem definition:
• Challenges in the commercialization pathway e.g. gaining market access
• Lack of formal value-based reimbursement procedures for diagnostic tests
Panaxea’s expertise:
• Developing a country-specific reimbursement roadmap and strategy (including
options for conditional as well as permanent reimbursement)
• Performing a detailed health technology assessment of the innovative test to
demonstrate its cost-effectiveness from a payer perspective and the diagnostic lab
perspective

11. Selection of our clients and partners
European
Commission
ZonMw
Roche
Thermofisher
TNO
Bayer
Belgian Health Care
Knowledge Centre
Fresenius
Mellon Medical
Acutus Medical
LeukoDx
Gannet
Portavita
Elekta
Sanofi
Nutricia
CSL Behring
H2020-ESCAPE-NET: European Sudden Cardiac Arrest network: towards Prevention, Education
and New Treatment
H2020-CRADL: Continuous Regional Analysis Device for neonate Lung
MAFEIP: Monitoring and Assessment Framework for the EIP on Active and Healthy Ageing
in collaboration with EC JRS

12. Team
Lotte M.G. Steuten, PhD, MSc
Chief Scientific Officer, Co-Founder
Isabelle Lepage-Nefkens, PhD,
MPH
Chief Executive Officer
Hubertus J.M. Vrijhoef, PhD, MSc
Chief Innovation Officer
Daan Mathijssen, MSc
Consultant
Anam Ahmed, MSc
Consultant
Liset Grooten, MSc
Affiliate Junior researcher
Janne Mewes, PhD
Senior consultant

13. Thank you!
@PANAXEA
The Health Intelligence Company
info@panaxea.eu